Active Biotech Research AB
Active Biotech Research AB is a company.
Active
Updated: ·
About
Active Biotech Research AB is a company.
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Active Biotech Research AB.
Active Biotech Research AB is a company.
Active Biotech Research AB is a company.
Key people at Active Biotech Research AB.
Active Biotech AB is a Swedish biotechnology company focused on developing immunomodulatory pharmaceuticals for cancer and inflammatory eye diseases. It targets unmet medical needs with a portfolio including small molecules like Tasquinimod (Phase Ib/IIa for hematological cancers such as myelofibrosis and multiple myeloma) and Laquinimod (Phase I for non-infectious uveitis), plus Naptumomab (Phase Ib/II for solid tumors, partnered with NeoTX Therapeutics).[1][2][3][4] The company serves patients with severe conditions where the immune system plays a key role, solving problems like tumor-promoting signals in bone marrow and severe inflammatory eye disorders through orally active drugs and antibody-based immunotherapy, with a lean team of 6 employees driving clinical progress from Lund, Sweden.[1][2]
Active Biotech AB was originally incorporated in 1983 and re-formed in 1998 as a spin-off from Pharmacia & Upjohn, leveraging expertise in immune system-related drug development.[1][2] Headquartered in Lund, Sweden, it has evolved from broad pharmaceutical R&D to a specialized focus on cancer (hematological malignancies and solid tumors) and inflammatory eye diseases, building on core competencies in early-to-late stage clinical development.[2] Key leadership includes CEO Helen Tuvesson, guiding a small, experienced team through collaborations with institutions like Abramson Cancer Center, MD Anderson, and Stanford Medicine.[1]
Active Biotech rides the wave of immuno-oncology and inflammatory disease therapies, where modulating the immune system addresses unmet needs in hematological cancers and uveitis amid rising demand for targeted, orally administered treatments.[2][3][4] Timing aligns with advances in small-molecule immunomodulators and antibody-drug conjugates, fueled by market forces like aging populations driving cancer prevalence and gaps in eye inflammation therapies.[1][3] It influences Sweden's biotech ecosystem as a Lund-based innovator, contributing to Nasdaq Stockholm's life sciences cluster through spin-off heritage and global partnerships that validate immune-focused R&D.[1][2]
Active Biotech's path forward centers on advancing Tasquinimod to later-stage data in myelofibrosis/multiple myeloma, completing Laquinimod's biodistribution study for uveitis, and monitoring NeoTX's Naptumomab progress in solid tumors.[2][3][4] Trends like precision immuno-therapies and eye disease breakthroughs will shape its trajectory, potentially expanding partnerships or licensing for commercialization. Its influence may grow by delivering first-in-class options for niche indications, reinforcing its niche as an agile immunology specialist in biotech. This positions it to capitalize on immune-centric innovation, echoing its spin-off roots in high-need therapeutics.[1][2][4]
Key people at Active Biotech Research AB.
